Search

The BRCA Founder Outreach study was recently launched to look at how patients undergo genetic screenings for cancer.

… Wednesday, April 25, 2018 Summary A new study led by MSK and three other cancer centers is looking at different aspects of testing for cancer genes. In March 2018, the US Food and Drug Administration approved an at-home, mail-in kit that tests for some of the inherited mutations in the genes BRCA1 and

Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou, China and New York on December 2, 2022.

… Wednesday, December 28, 2022 Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou

Kimberly Feigin, MD, has been named Chief of the Breast Imaging Service within the Department of Radiology.

… Monday, January 13, 2025 Kimberly Feigin, MD, has been named Chief of the Breast Imaging Service within the Department of Radiology . Dr. Feigin has been a member of the service for 22 years and most recently served as Interim Chief. Dr. Feigin also serves as the Head of Breast Imaging Quality Assurance

Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors.

… Monday, December 16, 2013 Summary Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors. Alexander Rudensky is Chair of the Immunology Program in the Sloan Kettering Institute

A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.

… Wednesday, November 1, 2017 Summary A majority of childhood solid tumors appear to be caused when a protein called PGBD5 scrambles DNA segments to cause genetic mutations. This PGBD5 activity in cancer cells also creates many breaks in the DNA, which the cells must repair in order to survive. A new treatment

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

… Monday, November 17, 2014 Summary A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors. For people with advanced breast cancer , several clinical trials have shown that experimental targeted drugs called PI3K inhibitors can

Researchers report a new method that may enable detection of a number of different types of cancer in the early stages.

… Thursday, August 13, 2020 Summary Collaborators from MSK and Weill Cornell Medicine report that tiny packages of materials released into the blood, called EVPs, may enable detection of a number of different types of cancer in the early stages. Because cancer is easier to successfully treat when it’s

Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

… Wednesday, March 20, 2013 Summary Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia. Doctors have traditionally had limited treatment options to offer adults with B cell acute lymphoblastic leukemia

MSK announces the establishment of The Tow Center for Developmental Oncology (TCDO).

… Monday, January 25, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the establishment of The Tow Center for Developmental Oncology (TCDO). TCDO will bring together the unique expertise of researchers and physicians from across MSK and empower them to pursue translational research projects

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, achieved several notable advances in 2024, including earning authorization to provide the first gene therapy for sickle cell disease and beta thalassemia, opening a new program for patients with desmoplastic small round cell tumors, translating groundbreaking tumor evolution insights into a new clinical trial strategy for patients with osteosarcoma, and leading cutting-edge research for improving patient outcomes after CAR T cell therapy.

… Thursday, December 19, 2024 Physicians and researchers at MSK Kids , Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, achieved several notable advances in 2024, including earning authorization to provide the first gene therapy for sickle cell disease and beta thalassemia,